Bio

Ashley Hudson is Associate Director of Formulation Research and Early Development at Syntis Bio with a PhD from Texas A&M University (2021), where her dissertation investigated bacterial bioenergetics and novel assay platforms for drug discovery. She has extensive experience in nutrition and metabolic research, having worked at Baylor College of Medicine's Children's Nutrition Research Center (ARS/USDA) after earning her bachelor's degree. Ashley brings industry experience in drug development for rare metabolic diseases, having previously worked at Synlogic Therapeutics, where she contributed to developing novel therapeutic formulations for orphan indications including phenylketonuria (PKU) and homocystinuria (HCU). At Syntis Bio, she continues this work at the intersection of enzyme engineering and rare disease drug development, advancing enzyme-based therapeutic approaches for underserved patient populations with inborn errors of metabolism. Based in Boston, MA, Ashley is dedicated to translating formulation science into meaningful treatments for the rare disease community.